These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7687149)

  • 1. 85Sr contaminant as a reliable tracer of 89Sr for monitoring urinary radioactivity in patients treated with 89Sr for bone metastases.
    De Agostini A; Mascaro L; Pizzocaro C; Panarotto MB; Bestagno M
    J Nucl Biol Med (1991); 1993 Mar; 37(1):38-44. PubMed ID: 7687149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone pain palliation with 85Sr therapy.
    Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
    J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N
    J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of 89Sr on the cell immune function in patients with multiple bone metastases].
    Wu YG; Ma QL; Liu GF
    Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):277-8. PubMed ID: 12575316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Possibilities of systemic radiotherapy with high-purity 89Sr chloride in the treatment of bone metastases].
    Fomin DK; Tararukhina OB; Nazarov AA
    Vestn Rentgenol Radiol; 2012; (2):29-31. PubMed ID: 22730757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Radioactive substances (32P and 89Sr) in the treatment of pain in bone metastases].
    Flamm J; Burkert S
    Z Urol Nephrol; 1981 Nov; 74(11):801-6. PubMed ID: 6172913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
    Breen SL; Powe JE; Porter AT
    J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strontium-89 for treatment of painful bone metastasis from prostate cancer.
    Altman GB; Lee CA
    Oncol Nurs Forum; 1996 Apr; 23(3):523-7. PubMed ID: 8801513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
    Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone pain palliation with strontium-89 in cancer patients with bone metastases.
    Giammarile F; Mognetti T; Resche I
    Q J Nucl Med; 2001 Mar; 45(1):78-83. PubMed ID: 11456379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy.
    Sciuto R; Festa A; Tofani A; Pasqualoni R; Semprebene A; Cucchi R; Ferraironi A; Rea S; Maini CL
    Clin Ter; 1998; 149(921):43-7. PubMed ID: 9621488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
    Papatheofanis FJ
    J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A direct measurement of strontium-89 activity in bone metastases.
    Ben-Josef E; Maughan RL; Vasan S; Porter AT
    Nucl Med Commun; 1995 Jun; 16(6):452-6. PubMed ID: 7675358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group.
    Piffanelli A; Dafermou A; Giganti M; Colamussi P; Pizzocaro C; Bestagno M;
    Q J Nucl Med; 2001 Mar; 45(1):100-7. PubMed ID: 11456368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting strontium-89 removable contamination using a sodium iodide well counter.
    Hackett MT; Coupal JJ; Perdikaris N
    J Nucl Med Technol; 1997 Sep; 25(3):195-200. PubMed ID: 9291066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A process for the recovery of strontium from the urine of patients injected with 89Sr.
    Argiro G; Atzei G; Boemi S; Cipriani C; Shukla SK; Rossi G; Sedda AF
    Appl Radiat Isot; 1998 Jul; 49(7):777-8. PubMed ID: 9570096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotoxicity after strontium-89 therapy for bone metastases using the micronucleus assay.
    Watanabe N; Yokoyama K; Kinuya S; Shuke N; Shimizu M; Michigishi T; Tonami N; Seto H; Goodwin DA
    J Nucl Med; 1998 Dec; 39(12):2077-9. PubMed ID: 9867144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.